Assessment of CEP55, PLK1 and FOXM1 expression in patients with bladder cancer in comparison with healthy individuals

References

• Ather MH, Nazim SM. New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer. Korean J Urol. 2015;56(8):553–564.
   PubMedGoogle Scholar
• Adejoro O, Alishahi A, Konety B. Association of comorbidity, age, and radical surgical therapy for prostate cancer, bladder cancer, and renal cell carcinoma. Urology. 2016;97:130–137.
   PubMedGoogle Scholar
• Jeffery J, Sinha D, Srihari S, Kalimutho M, Khanna K. Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis. Oncogene. 2016;35(6):683–690.
   PubMed Web of Science ®Google Scholar
• Chen C-H, Lai J-M, Chou T-Y, Chen C-Y, Su L-J, Lee Y-C, et al. VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PloS One. 2009;4(4):e5052.
   PubMed Web of Science ®Google Scholar
• Chen C-H, Lu P-J, Chen Y-C, Fu S-L, Wu K-J, Tsou A-P, et al. FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway. Oncogene. 2007;26(29):4272–4283.
   PubMed Web of Science ®Google Scholar
• Singh P, Srivastava AK, Rath S, Dalela D, Goel M, Bhatt M. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma. Immunobiology. 2015;220(1):103–108.
   PubMed Web of Science ®Google Scholar
• Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta. 2007;1775(1):92–102.
   PubMed Web of Science ®Google Scholar
• Korver W, Roose J, Heinen K, Weghuis DO, de Bruijn D, van Kessel AG, Clevers H. The human TRIDENT/HFH-11/FKHL16 gene: structure, localization, and promoter characterization . Genomics. 1997;46(3):435–442.
   PubMed Web of Science ®Google Scholar
• Koo C-Y, Muir KW, Lam EW-F. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta. 2012;1819(1):28–37.
   PubMed Web of Science ®Google Scholar
• Uddin S, Ahmed M, Hussain A, Abubaker J, Al-Sanea N, AbdulJabbar A, et al. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol. 2011;178(2):537–547.
   PubMed Web of Science ®Google Scholar
• Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, et al. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. International Journal of Radiation Oncology* Biology* Physics. 2010;77(1):253–260.
   PubMed Web of Science ®Google Scholar
• Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, et al. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Anticancer Drugs. 2011;22(5):444–453.
   PubMed Web of Science ®Google Scholar
• He Z, Wu J, Dang H, Lin H, Zheng H, Zhong D. Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression. Cancer Lett. 2011;303(2):92–98.
   PubMed Web of Science ®Google Scholar
• Park JS, Sohn HJ, Park GS, Chung YJ, Kim TG. Induction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models. Cancer Sci. 2011;102(8):1448–1454.
   PubMed Web of Science ®Google Scholar
• Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbayo M, Segersten U, et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol. 2012;180(5):1824–1834.
   PubMed Web of Science ®Google Scholar
• Liu D, Zhang Z, Kong C-Z. High FOXM1 expression was associated with bladder carcinogenesis. Tumour Biol. 2013;34(2):1131–1138.
   PubMedGoogle Scholar
• Zhang Z, Zhang G, Kong C, editors. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urologic Oncology: Seminars and Original Investigations; 2013: Elsevier.
   Google Scholar
• de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest. 2005;85(1):154–159.
   PubMed Web of Science ®Google Scholar
• Shirodkar SP, Lokeshwar VB. Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol. 2009;19(5):488–493.
   PubMed Web of Science ®Google Scholar
• Pignot G, Vieillefond A, Vacher S, Zerbib M, Debre B, Lidereau R, et al. Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Br J Cancer. 2012;106(6):1177–1186.
   PubMed Web of Science ®Google Scholar
• Andersson KE, McCloskey KD. Lamina propria: the functional center of the bladder? Neurourol Urodyn. 2014;33(1):9–16.
   PubMed Web of Science ®Google Scholar
• Martin KJ, Patrick DR, Bissell MJ, Fournier MV. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One. 2008;3(8):e2994.
   PubMed Web of Science ®Google Scholar
• Wang I-C, Chen Y-J, Hughes D, Petrovic V, Major ML, Park HJ, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Molecular and Cellular Biology. 2005;25(24):10875–10894.
   PubMed Web of Science ®Google Scholar
• Laoukili J, Kooistra MRH, Brás A, Kauw J, Kerkhoven RM, Morrison A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 2005;7(2):126–136.
   PubMed Web of Science ®Google Scholar
• Wolter P, Hanselmann S, Pattschull G, Schruf E, Gaubatz S. Central spindle proteins and mitotic kinesins are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy. Oncotarget. 2017;8(7):11160–11172.
   PubMedGoogle Scholar
• Jeffery J, Sinha D, Srihari S, Kalimutho M, Khanna K. Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis. Oncogene. 2015.
   PubMed Web of Science ®Google Scholar
• Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print. Int J Urological Nursing. 2007;1(2):94.
   Google Scholar
• Waseem A, Ali M, Odell EW, Fortune F, Teh MT. Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol. 2010;46(7):536–542.
   PubMed Web of Science ®Google Scholar
• Janus JR, Laborde RR, Greenberg AJ, Wang VW, Wei W, Trier A, et al. Linking expression of FOXM1, CEP55 and HELLS to tumorigenesis in oropharyngeal squamous cell carcinoma. Laryngoscope. 2011;121(12):2598–2603.
   PubMed Web of Science ®Google Scholar
• Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M, et al. FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One. 2009;4(3):e4849.
   PubMed Web of Science ®Google Scholar
• Heijink IH, de Bruin HG, van den Berge M, Bennink LJC, Brandenburg SM, Gosens R, et al. Role of aberrant WNT signalling in the airway epithelial response to cigarette smoke in chronic obstructive pulmonary disease. Thorax. 2013;68(8):709–716.
   PubMed Web of Science ®Google Scholar
• Andres SA, Bickett KE, Alatoum MA, Kalbfleisch TS, Brock GN, Wittliff JL. Interaction between smoking history and gene expression levels impacts survival of breast cancer patients. Breast Cancer Res Treat. 2015;152(3):545–556.
   PubMed Web of Science ®Google Scholar